Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

The Tipping Point from Genome Instability to Cancer

Project description

Understanding the role of genome instability in cancer development

Cancer often begins developing years or even decades before diagnosis, yet its early stages remain poorly understood. The ERC-funded Unstable Genome project explores how genome instability contributes to tumour initiation, with a focus on chromosome instability (CIN) in precancerous conditions. The project hypothesises that CIN serves as a tipping point for precancerous clones, facilitating malignancy. It will study CIN-driven tumour development in organs with different regenerative capacities, particularly the brain and gut. Researchers will compare CIN patterns in normal and tumour cells from post-mortem brain tissue to identify features that distinguish cancer-causing clones. In mouse models, the project will assess how CIN provides selective advantages, helps clones evade immune surveillance, and quantifies its role in tumour progression.

Objective

Cancer starts years to decades before diagnosis. Yet, early stages of tumor development are poorly understood. In particular, the precancer landscape of chromosome instability (CIN) is understudied, due to the scarcity of precursor lesions and methods to analyze CIN in single cells. The research presented here will address how the instability rate of the genome, followed by selection, determines whether a CIN-driven tumor arises. I hypothesize that the onset of CIN is the tipping point that governs the fate of a precancer clone. Using spatially aware and single-cell multiome methods that we developed, we will dissect essential factors that lead to malignancy via CIN, including extrachromosome circular DNAs. We will analyze two solid tissues at opposite ends of the cell turnover spectrum, which deeply diverge in regeneration capacity, clonality and constraints, namely the brain and the gut.

Aim 1 will assess the instability rate of the human genome using the postmortem brain as a model tissue. CIN patterns vary greatly in frequency and type across brain tumors; we will compare the background incidence of fundamental types of CIN in normal cells to CIN signatures after selection has acted, in diagnosed tumors of the same lineages.

Aim 2 will dissect CIN in space and time from the cell of origin, to identify what discriminates nascent clones that may cause cancer from those that do not. Timecourses in mouse models will reveal how CIN contributes to selective advantages and how nascent CIN-positive clones escape elimination by immune cells.

Aim 3 leverages human precursor lesions to probe the role of CIN as a central gatekeeper between tumor initiation and growth, using the gut as a longitudinal in vivo system to directly capture the tipping point to cancer.

Unstable Genome will provide the first systematic quantification of the early development of chromosomally unstable lesions and reveal the principles that govern CIN-driven clone expansion in vivo.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC - HORIZON ERC Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2024-COG

See all projects funded under this call

Host institution

DEUTSCHES KREBSFORSCHUNGSZENTRUM HEIDELBERG
Net EU contribution
€ 2 000 000,00
Address
IM NEUENHEIMER FELD 280
69120 Heidelberg
Germany
Region
Baden-Württemberg Karlsruhe Heidelberg, Stadtkreis
Activity type
Research Organisations
Links
Total cost
€ 2 000 000,25

Beneficiaries (1)